The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
Open accessAbstract
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-particle radiation to prostate cancer. We determined its radiation dosimetry and relationships to pretherapeutic imaging and outcomes. Methods: Thirty patients with prostate cancer receiving 177Lu-PSMA-617 within a prospective clinical trial (ACTRN12615000912583) were studied. Screening 68Ga-PSMA-11 PET/CT demonstrated high PSMA expression in all patients. After therapy, patients underwent quantitative SPECT/CT at 4, 24, and 96 h. Pharmacokinetic uptake and clearance at a voxel level were calculated and translated into absorbed dose using voxel S values. Volumes of interest were drawn on normal tissues and tumor to assess radiation dose, and a whole-body tumor dose was defined. Correlations between PSMA PET/CT parameters, dosimetry, and biochemical and therapeutic response were analyzed to identify relationships between absorbed dose, tumor burden, and patient physiology. Results: Mean absorbed dose to kidneys, submandibular and parotid glands, liver, spleen, and bone marrow was 0.39, 0.44, 0.58, 0.1, 0.06, and 0.11 Gy/MBq, respectively. Median whole-body tumor-absorbed dose was 11.55 Gy and correlated with prostate-specific antigen (PSA) response at 12 wk. A median dose of 14.1 Gy was observed in patients achieving a PSA decline of at least 50%, versus 9.6 Gy for those achieving a PSA decline of less than 50% (P < 0.01). Of 11 patients receiving a tumor dose of less than 10 Gy, only one achieved a PSA response of at least 50%. On screening PSMA PET, whole-body tumor SUVmean correlated with mean absorbed dose (r = 0.62), and SUVmax of the parotids correlated with absorbed dose (r = 0.67). There was an inverse correlation between tumor volume and mean dose to the parotids (r = −0.41) and kidneys (r = −0.43). The mean parotid dose was also reduced with increasing body mass (r = −0.41) and body surface area (r = −0.37). Conclusion:177Lu-PSMA-617 delivers high absorbed doses to tumor, with a significant correlation between whole-body tumor dose and PSA response. Patients receiving less than 10 Gy were unlikely to achieve a fall in PSA of at least 50%. Significant correlations between aspects of screening 68Ga-PET/CT and tumor and normal tissue dose were observed, providing a rationale for patient-specific dosing. Reduced salivary and kidney doses were observed in patients with a higher tumor burden. The parotid dose also reduced with increasing body mass and body surface area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This scenario is common for many RPTs agents, and perhaps most prominently for prostate cancer ( 39 , 40 ), where metastatic dissemination is coincident with the marrow.”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a phase 2 study of 28 patients who underwent 51 Cr-EDTA GFR measurement before and 3 mo after completion of 4 cycles of 177 Lu-PSMA, a very modest decline of approximately 12 mL/min in GFR was noted ( 39 , 68 , 69 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The dosimetry studies of small molecules targeting PSMA such as 124 I/ 131 I-MIP-1095, or 177 Lu-PSMA-617 or 177 Lu-PSMA I&T have shown salivary glands commonly receive the highest radiation-absorbed dose among normal organs ( 69 , 74 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [69]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a phase 2 study of 28 patients who underwent 51 Cr-EDTA GFR measurement before and 3 mo after completion of 4 cycles of 177 Lu-PSMA, a very modest decline of approximately 12 mL/min in GFR was noted ( 39 , 68 , 69 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredIn the citing paper
“High SUVmean values indicate high average PSMA expression levels, which may promote tumor binding and uptake of 177Lu-PSMA-617, leading to greater delivery of radiation and greater antitumor activity (18,19).”
From Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial) (2024) · cites this paper as [19]
In the citing paper
“High SUVmean values indicate high average PSMA expression levels, which may promote tumor binding and uptake of 177Lu-PSMA-617, leading to greater delivery of radiation and greater antitumor activity (18,19).”
From Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial) (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Self-citationAfshar‐Oromieh, A., Avtzi, E., Giesel, F. L., Holland‐Letz, T., Linhart, H., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Jan, S., Benoit, D., Becheva, E., Carlier, T., Cassol-Brunner, F., Descourt, P., Frisson, T., Grevillot, L., Guigues, L., Maigne, L., et al. (2011) · Physics in Medicine and Biology · doi:10.1088/0031-9155/56/4/001 · Cited by 797
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H., Heck, M. M., Kübler, H. R., Beer, A. J., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 778
Radiotherapy Dose–Volume Effects on Salivary Gland Function
Deasy, J. O., Moiseenko, V., Marks, L. B., Chao, K. S. C., Nam, J., & Eisbruch, A. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.090 · Cited by 591
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572
Research works printed but not linked: 1
- Fendler, 2016, 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer [in German], Nucl Med (Stuttg)., 55, 123
Cited by
Sorted by citations
Items 201–300 of 504
Tuchayi, A. M., Yadav, S., Jiang, F., Kim, S. T., Saelee, R., Morley, A., Juarez, R., Lawhn-Heath, C. A., Wang, Y., de Kouchkovsky, I., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266842 · Cited by 19
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
Eapen, R. S., Williams, S., Macdonald, S., Keam, S. P., Lawrentschuk, N., Au, L., Hofman, M. S., Murphy, D. G., & Neeson, P. J. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00913-8 · Cited by 16
“Lutetium PSMA also emits γ-radiation that enable effective imaging, giving information about tumour localization and dosimetry 49,61,62 .”
InfluentialSelf-citationSharpening the Blade of Precision Theranostics
Currie, G. M., & ROHREN, E. M. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.01.007 · Cited by 16
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
Shah, H., Ravi, P. K., Sonpavde, G., & Jacene, H. A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2139679 · Cited by 17
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
Calais, J., Morris, M. J., Kendi, A. T., Kalebasty, A. R., Tutrone, R. F., Jr., Anderson, M. J., & Sartor, O. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268363 · Cited by 19
Yazdani, E., Neizehbaz, A., Ziarati, N. K., Emami, F., Vosoughi, H., Asadi, M., Mahmoudi, A., Sadeghi, M., Kheradpisheh, S. R., & Geramifar, P. (2025) · Medical Physics · doi:10.1002/mp.70030 · Cited by 15
“…it ideal for prospective modelling; (3) prior studies have shown that PET uptake correlates with post-therapy AD,supporting its predictive value 8,28 (4) PET-based MC simulations provide practical training data for ML, especially when SPECT dosimetry is unavailable or limited; and (5) PET-based…”
Widjaja, L., Derlin, T., Roß, T. L., Bengel, F. M., & Werner, R. A. (2021) · The Prostate · doi:10.1002/pros.24250 · Cited by 15
“However, in our study, there was no association between PSMA signal on pretherapeutic PET/CT, renal function, and subsequent risk of CKD under RLT. Future studies may also investigate whether such interrelations can be detected for other PSMA‐ligands, for example, F‐18‐PSMA‐1007, or optimized imaging protocols.41 More…”
InfluentialMalcolm, J., Falzone, N., Gains, J. E., Aldridge, M. D., Mirando, D. M., Lee, B. Q., Gaze, M. N., & Vallis, K. A. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00436-4 · Cited by 15
Novel radionuclide therapy combinations in prostate cancer
Inderjeeth, A., Iravani, A., Subramaniam, S., Conduit, C., & Sandhu, S. K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187202 · Cited by 16
Self-citationStandardized PSMA-PET Imaging of Advanced Prostate Cancer
Seifert, R., Gafita, A., Telli, T., Voter, A. F., Herrmann, K., Pomper, M. G., Hadaschik, B. A., Rowe, S. P., & Fendler, W. P. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.005 · Cited by 16
PSMA-PET improves deep learning-based automated CT kidney segmentation
Leube, J., Horn, M., Hartrampf, P. E., Buck, A. K., Laßmann, M., & Tran‐Gia, J. (2023) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2023.08.006 · Cited by 15
“…other typical organs at risk in RPT, the bladder, the submandibular and parotid glands, and the kidneys exhibit increased accumulation of PSMA and, consequently, are exposed to a higher absorbed dose [3] and are therefore considered a possible organ at risk that can result in treatment limitations.”
BackgroundDyer, M. R., Jing, Z., Duncan, K., Godbe, J. M., & Shokeen, M. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108879 · Cited by 17
Ritt, P., Fernández, R., Soza‐Ried, C., Nicolai, H. E., Horacio Amaral, P., Krieger, K., Mapanao, A. K., Rotger, A., Zhernosekov, K., Schibli, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07102-8 · Cited by 15
Kurkowska, S., Brosch-Lenz, J., Dewaraja, Y. K., Frey, E. C., Sunderland, J. J., & Uribe, C. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268612 · Cited by 15
Deshayes, E., Fersing, C., Thibault, C., Roumiguié, M., Pourquier, P., & Houédé, N. (2023) · Cancers · doi:10.3390/cancers15123133 · Cited by 16
“In this study, injected activities were adjusted for patients’ weight, renal function and tumor burden (the injected activity was increased as a function of number of tumor sites to take into consideration the “tumor sink effect”) [46].”
Djekidel, M. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1213714 · Cited by 14
Straub, M., Kupferschläger, J., Serna-Higuita, L. M., Weissinger, M., Dittmann, H., la Fougère, C., & Fiz, F. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264770 · Cited by 16
“Existing data on (177)Lu-PSMA-617 RLT dosimetry indicate that the radiation dose delivered to the target is key in ensuring response (21,22).”
Dierks, A., Gäble, A., Rinscheid, A., Wienand, G., Pfob, C. H., Kircher, M., Enke, J. S., Janzen, T., Patt, M., Trepel, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266741 · Cited by 14
Carter, L. M., Ramos, J. C. O., & Kesner, A. (2021) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ac1550 · Cited by 14
Ma, K. K., Harmon, S. A., Klyuzhin, I. S., Rahmim, A., & Türkbey, B. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.09.002 · Cited by 14
Staanum, P. F. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00561-8 · Cited by 14
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions
Bent, E. H., & Morris, M. J. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01686-y · Cited by 16
PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives
Sandhu, K., Chen, D. C., Hennes, D. M. Z. B., Murphy, D. G., Lawrentschuk, N., & Perera, M. (2025) · Cancers · doi:10.3390/cancers17223717 · Cited by 15
“To manage these complexities, adaptive dosage algorithms, adjusting cumulative [ 177 Lu]Lu-PSMA-617 activity based on residual uptake, are being examined to individualise treatment cycles [43,45,46].”
Self-citationCaracciolo, M., Castello, A., Castellani, M., Bartolomei, M., & Lopci, E. (2024) · Biomedicines · doi:10.3390/biomedicines12102355 · Cited by 13
“In fact, it is well known that some patients respond to RLT and others respond poorly, probably due to individual differences in radiopharmaceutical distribution in malignant lesions, which cause variation in the adsorbed tumor dose [45].”
BackgroundHu, J., Seifert, R., Karkampouna, S., Gomes, C. V., Xue, S., Afshar‐Oromieh, A., Rominger, A., & Shi, K. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07010-3 · Cited by 14
Murthy, V., Ludwig, V. B., Gafita, A., Hope, T. A., & Calais, J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268818 · Cited by 13
Verburg, F. A., Nonnekens, J., Konijnenberg, M., & de Jong, M. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05147-5 · Cited by 13
PSMA theragnostics for metastatic castration resistant prostate cancer
Hong, S., Guja, K. E., & Iagaru, A. H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101438 · Cited by 13
Alsadi, R., Bouhali, O., Dewji, S. A., & Djekidel, M. (2022) · The Oncologist · doi:10.1093/oncolo/oyac216 · Cited by 13
Groener, D., Wichert, J., Adams, M., Mader, N., Klimek, K., Ngoc, C. N., Baumgarten, J., Happel, C., Mandel, P. C., Chun, F. K. ‐., et al. (2023) · Cancers · doi:10.3390/cancers15153878 · Cited by 12
“found higher tumor volume to result in lower intratherapeutic organ doses in both salivary glands and kidneys, which are both potential organs at risk [32].”
BackgroundRinscheid, A., Gäble, A., Wienand, G., Pfob, C. H., Dierks, A., Kircher, M., Trepel, M., Weckermann, D., Lapa, C., & Bundschuh, R. A. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265970 · Cited by 12
Zou, Y., Huang, M., Hu, M., Wang, H., Chen, W., & Tian, R. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00066 · Cited by 12
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer
Soon, Y. Y., Marschner, I. C., Schou, I. M., Hofman, M. S., Emmett, L., Davis, I. D., Stockler, M. R., & Martin, A. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33863 · Cited by 12
Self-citation360° CZT-SPECT/CT cameras: 99mTc- and 177Lu-phantom-based evaluation under clinical conditions
Hoog, C., Koulibaly, P.-M., van Sas, N. C. F., Imbert, L., Rouzic, G. L., Popoff, R., Badel, J., & Ferrer, L. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00684-6 · Cited by 12
“This study focuses on both 99m-Technetium ( 99m Tc), probably the most used isotope in conventional nuclear medicine [27], and 177 Lu which is an extremely challenging radionuclide in terms of theranostics, quantification and dosimetry [28–34].”
MethodAre FAP Theranostics Really Happening? Will Radiochemistry or Biology Win?
Hicks, R. J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267547 · Cited by 12
Self-citationPotent candidates for Targeted Alpha Therapy (TAT)
Filosofov, D. V., Baimukhanova, A., Khushvaktov, J., Kurakina, E. S., & Radchenko, V. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109027 · Cited by 12
Kafka, M., Eder, I. E., Klocker, H., & Heidegger, I. M. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.05.025 · Cited by 12
Dieudonné, A., Bailly, C., Cachin, F., Edet‐Sanson, A., Kraeber‐Bodéré, F., Hapdey, S., Merlin, C., Robin, P., Salaün, P., Schwartz, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06568-8 · Cited by 14
“Regarding lesion dosimetry, it is associated with blood prostate–specific antigen (PSA) [30] for [ 177 Lu]Lu-PSMA and with radiological response [31] for [ 177 Lu]Lu-DOTA-TATE, but not with PFS or OS.”
MethodMeher, N., Ashley, G. W., Bobba, K. N., Wadhwa, A., Bidkar, A. P., Dasari, C., Mu, C., Sankaranarayanan, R. A., Cámara, J. A., Raveendran, A., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304618 · Cited by 12
Bodei, L., Tuttle, R. M., Grewal, R. K., Mauguen, A., Augensen, F., Abusamra, M., Mahajan, S., Jayaprakasam, V. S., Osborne, J. R., Haque, S. S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06420-z · Cited by 12
Feuerecker, B., Gafita, A., Langbein, T., Tauber, R., Seidl, C., Bruchertseifer, F., Gschwendt, J., Weber, W., D’Alessandria, C., Morgenstern, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316845 · Cited by 12
Prostate Cancer Radioligand Therapy
Yechiel, Y., Chicheportiche, A., Keidar, Z., & Ben‐Haim, S. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.011 · Cited by 11
Handayani, W., Chantadisai, M., Phromphao, B., Noipinit, N., Pasawang, P., & Khamwan, K. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01960-2 · Cited by 11
“In line with our results, higher doses for all organs by the planar method were reported in most of several studies of 177 Lu dosimetry [8, 18–21].”
Ho, K., Tatum, D. S., Watkinson, L. D., Carmack, T. L., Jia, F., Mascioni, A., Maitz, C. A., Magda, D. J., & Anderson, C. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267667 · Cited by 11
Wu, S., Hu, W., Chen, M., Xiao, X., & Liu, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-77889-3 · Cited by 11
Localized In Vivo Prodrug Activation Using Radionuclides
Quintana, J. M., Jiang, F., Kang, M., Onecha, V. V., Könik, A., Qin, L., Rodriguez, V. E., Hu, H., Borges, N., Khurana, I., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268559 · Cited by 11
The Emerging Role of Next-Generation Imaging in Prostate Cancer
Murthy, V., Aggarwal, R. R., & Koo, P. J. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01156-1 · Cited by 11
Parent, E. E., & Kase, A. M. (2022) · Cancers · doi:10.3390/cancers14174276 · Cited by 11
“This need to augment 177 Lu PSMA-617 dosage is underscored by a study that showed that patients receiving less than 10 Gy to tumors were unlikely to achieve a PSA response ( ≥ 50% PSA decline in pretreatment PSA) [41].”
Swiha, M. M., Ayati, N., Oprea‐Lager, D. E., Ceci, F., & Emmett, L. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.007 · Cited by 12
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives
Volpe, F., Nappi, C., Piscopo, L., Zampella, E., Mainolfi, C. G., Ponsiglione, A., Imbriaco, M., Cuocolo, A., & Klain, M. (2023) · Cancers · doi:10.3390/cancers15194746 · Cited by 11
“177Lu-PSMA can prolong PC patients’ survival, but cannot always inhibit progression, usually to bone but also to liver [155].”
BackgroundOverlooked potential of positrons in cancer therapy
Hioki, T., Gholami, Y. H., McKelvey, K. J., Aslani, A., Marquis, H., Eslick, E. M., Willowson, K. P., Howell, V. M., & Bailey, D. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81910-4 · Cited by 11
Assessing the Correlation Between68Ga-PSMA-11 Renal PET Parameters and Renal Function Tests
Schierz, J., Sarikaya, İ., Albatineh, A. N., & Sarıkaya, A. (2021) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.121.262462 · Cited by 11
“PSMA ligands radiolabeled with 177 Lu and 225 Ac are also used to treat prostate cancer metastases, with increasing success ( 10,11 ).”
MethodHofman, M. S., & Emmett, L. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.030 · Cited by 11
Self-citationSandhu, S., Joshua, A. M., Emmett, L., Bressel, M., Anton, A., Spain, L., Horvath, L. G., Pasam, A., Tolmeijer, S. H., Akhurst, T., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00017-3 · Cited by 13
Self-citationParihar, A. S., Hofman, M. S., & Iravani, A. (2022) · Radiology · doi:10.1148/radiol.220859 · Cited by 10
Self-citationIs There a Role of Artificial Intelligence in Preclinical Imaging?
Küper, A. T., Blanc‐Durand, P., Gafita, A., Kersting, D., Fendler, W. P., Seibold, C., Moraitis, A., Lückerath, K., James, M. L., & Seifert, R. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.003 · Cited by 10
Fele‐Paranj, A., Saboury, B., Uribe, C., & Rahmim, A. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00236-w · Cited by 10
Yadav, S., Jiang, F., Kurkowska, S., Saelee, R., Morley, A., Feng, F. Y.-C., Aggarwal, R. R., Lawhn-Heath, C. A., Uribe, C., & Hope, T. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267208 · Cited by 11
Kao, Y. H., Falzone, N., Pearson, M., & Sivaratnam, D. A. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.267067 · Cited by 11
Karimzadeh, A., Schatz, L., Sauer, M., Apostolova, I. I., Buchert, R., Klutmann, S., & Lehnert, W. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00668-6 · Cited by 10
“However, opposing results were also reported for [ 177 Lu]Lu-PSMA-617 [6–8 , 47 ].”
BackgroundMethodResultInfluentialBogsrud, T. V., Engelsen, O., Lu, T. T. T., Stensvold, A., Johnson, D. R., Burkett, B. J., Kendi, A. T. K., Pandey, M. K., Sundset, R., & Durski, J. M. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01156-9 · Cited by 10
Gäble, A., Dierks, A., Rinscheid, A., Patt, M., Wienand, G., Pfob, C. H., Kircher, M., Fukushima, K., Nikolić, A. A., Enke, J. S., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06959-5 · Cited by 10
A machine learning-based model for a dose point kernel calculation
Scarinci, I., Valente, M., & Pérez, P. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00560-9 · Cited by 10
“Several approaches for internal dose estimation in nuclear medicine procedures have been developed, such as Monte Carlo (MC) transport simulation [12, 13], S-value estimation [14, 15], and dose point kernel (DPK) convolution [16, 17].”
MethodHa, S., Joo Hyun, O., Park, C., Boo, S. H., Yoo, I. R., Moon, H. W., Yoon, D., & Lee, J. Y. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2023.0656 · Cited by 10
“Dosimetry of the commercially available [ 177 Lu]Lu-PSMA-617 showed rapid clearance from the blood pool as could be expected from small molecules, with a mean total body time-integrated activity coefficient of 37.9 ± 14.6 hours (h) reported [4,5].”
BackgroundInfluentialIsrael, J. S., Marcelin, L.-M., Thomas, C., Szczyrbová, E., Fuessel, S., Puhr, M., Linxweiler, J., Yalala, S., Zwart, W. T., Baniahmad, A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03125-5 · Cited by 10
“He introduced the audience to studies investigating absorbed dose, standardised uptake value (SUV), or PSA 50 value, which can be associated with total tumour volume and OS [24, 82, 83].”
BackgroundFacile transmetallation of [Sb III (DOTA)] − renders it unsuitable for medical applications
Chen, C., Sommer, C., Thisgaard, H., McKee, V., & McKenzie, C. J. (2022) · RSC Advances · doi:10.1039/d2ra00642a · Cited by 9
Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies
Faustino‐Rocha, A. I., Baptista, C. J., Nascimento-Gonçalves, E., & Oliveira, P. A. (2022) · Anticancer Research · doi:10.21873/anticanres.16167 · Cited by 11
Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
Franco, M. D., Mei, R., Garcia, C., & Fanti, S. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241258367 · Cited by 9
Pre- or post-chemotherapy: effect on PSMA uptake
Yadav, S., Tuchayi, A. M., Moradpour, M., Jiang, F., Juarez, R., de Kouchkovsky, I., Flavell, R. R., Aggarwal, R. R., & Hope, T. A. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01229-3 · Cited by 9
Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics
Davis, L., Smith, A.-L., Aldridge, M. D., Foulkes, J., Peet, C., Wan, S., Gains, J. E., Bomanji, J. B., & Gaze, M. N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040174 · Cited by 9
“There is a good correlation between 68Ga PSMA and 177Lu PSMA distribution, allowing for pre-therapeutic dosimetric calculation to be performed in order to minimise toxicity (Figure 2C,D) [32].”
BackgroundPET imaging of new target CDK19 in prostate cancer
Dai, D., Jiang, Y. X., Huang, T., Li, Y., Wang, Z., Yang, S., Li, S., Li, D., Hou, W., Li, D., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06277-2 · Cited by 9
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Handke, A. E., Kesch, C. V., Fendler, W. P., Telli, T., Liu, Y., Hakansson, A. K., Davicioni, E., Hughes, J. D., Hong, S., Lückerath, K., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007354 · Cited by 9
177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
Cao, J., Chen, Y., Hu, M. L., & Zhang, W. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01649-w · Cited by 9
Schneider, C., Täger, P., Hammes, J., Fischer, T. H., Drzezga, A. E., Pfister, D. J. K. P., Heidenreich, A., & Schmidt, M. C. (2021) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1670-9500 · Cited by 9
PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?
Kong, G., & Hicks, R. J. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102293 · Cited by 9
Self-citationKazemi-Jahromi, M., Yazdani, E., Ziarati, N. K., Asadi, M., Sadeghi, M., & Geramifar, P. (2024) · International Journal of Radiation Biology · doi:10.1080/09553002.2024.2404448 · Cited by 8
Borges, N., Losee, M., Liu, M., Cheng, S., Könik, A., Ritzer, J., Wolanski, A., Ng, T. S. C., Choudhury, A. D., Taplin, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07541-3 · Cited by 9
Chen, D. C., Buteau, J. P., Papa, N. P., Akhurst, T. J., Alipour, R., Bollampally, N., Cardin, A., Eifer, M., Casanueva-Eliceiry, S., Jackson, P. A., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270804 · Cited by 9
Self-citationChallenges and Opportunities in Radioligand Therapy
Currie, G. M., & Bailey, D. L. (2025) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.270169 · Cited by 8
“2) in target and non-target tissues, independently of whether the diagnostic/ therapeutic pair is a true theranostic ( 10 , 18 , 34 ).”
Aksu, A., Topuz, Ö. V., Yilmaz, B., Şen, N. P. K., Acar, E., & Kaya, G. Ç. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001539 · Cited by 8
Chen, J., Qi, L., Tang, Y., Tang, G., Gan, Y., & Cai, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.958180 · Cited by 9
IDO promotes the proliferation and invasion of prostate cancer cells through KYNU
Zhou, H., Wang, W., Liu, M., Xie, P., Deng, T., Peng, J., & Xu, C. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01316-y · Cited by 8
Mader, N., Schoeler, C., Pezeshkpour, N., Klimek, K., Groener, D., Happel, C., Tselis, N., Mandel, P. C., Grünwald, F., & Sabet, A. (2023) · Cancers · doi:10.3390/cancers15184605 · Cited by 8
“As a result, patients with oligometastatic disease and low tumor burden show an increased absorbed dose per administered activity (GBq/Gy) in critical organs [14].”
Foxton, C., Waldron, B. P., Grønlund, R. V., Simon, J., Cornelissen, B. T., O’Neill, E. S., & Stevens, D. J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268508 · Cited by 8
“177 Lu-PSMA-617 data from prospective clinical trials suggest that providing a greater absorbed radiation dose to the tumor may achieve improved outcomes, such as a greater PSA response ( 8,9 ).”
Ritt, P., Jobic, C., Beck, M., Schmidkonz, C., Kuwert, T., Uder, M., & Brand, M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243782 · Cited by 8
“There is an indication that personalized, dosimetry-based dosing could lead to increased tumor doses (24) and better response rates (25).”
BackgroundHope, T. A., & Calais, J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00349-4 · Cited by 8
Rasul, S., Wollenweber, T., Zisser, L., Kretschmer‐Chott, E., Grubmüller, B., Kramer, G., Shariat, S. F., Eidherr, H., Mitterhauser, M., Vraka, C., et al. (2021) · Cancers · doi:10.3390/cancers13102489 · Cited by 8
“The reason lies in the crucial role of radiation dosimetry in estimating the therapy response and level of absorbed radiation dose, not only for each individual metastasis but also for the organs physiologically exhibiting an uptake of PSMA-RLT [27] and thereby evaluating their degree of therapy toxicity [28].”
BackgroundThe Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics
Hofman, M. S. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266930 · Cited by 7
Self-citationSiripongsatian, D., Jantarato, A., Promteangtrong, C., Kunawudhi, A., Kiatkittikul, P., Boonkawin, N., Yaset, S., Somboon, S., & Chotipanich, C. (2024) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.1055/s-0044-1779634 · Cited by 7
“4 Notably, high PSMA expression can also serve as a marker for aggressive tumor phenotypes.”
BackgroundAlkahtani, T. O. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01571-x · Cited by 7
Automatic bone marrow segmentation for precise [ 177 Lu]Lu‐PSMA‐617 dosimetry
Lu, Z., Hu, J., Chen, G., Jiang, H., Shih, C., Afshar‐Oromieh, A., Rominger, A., Shi, K., & Mok, G. S. P. (2025) · Medical Physics · doi:10.1002/mp.17684 · Cited by 7
Bilinska, A., Kumar, N., V, Gnesin, S., Läppchen, T., Menéndez, E., Martin, M., Rösch, F., Rominger, A., & Gourni, E. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07565-9 · Cited by 7
Viscuse, P. V., Devitt, M. E., & Dreicer, R. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267006 · Cited by 7
“…study of men with mCRPC treated with 177 Lu-PSMA-617 suggests that the response to treatment can be predicted by the dose to the tumor, as 10 of 11 patients who received less than 10Gy to the tumor did not have a PSA decline of 50% or more, providing a rationale for patient-speci fi c dosing ( 52 ).”
MethodSiebinga, H., der Veen, B. J. D. W., de Vries–Huizing, D. M. V., Vogel, W. V., Hendrikx, J. J. M. A., & Huitema, A. D. R. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00642-2 · Cited by 7
Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
O’Neill, E. S., & Cornelissen, B. T. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.02.004 · Cited by 7
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review
Jia, A. Y., Kashani, R., Zaorsky, N. G., Baumann, B. C., Michalski, J. M., Zoberi, J. E., Kiess, A. P., & Spratt, D. E. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.01.012 · Cited by 7
In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177
Boas, C. A. W. V., Silva, J. D. J., Dias, L. A. P., Freire, M. R. B., Balieiro, L. M., dos Santos, C. S. F., Vivaldini, B. F., Benedetto, R., Vieira, D. P., Passos, P. D. Q. S., et al. (2021) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2021.110064 · Cited by 7
Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass
Ling, S. W., Veldt, A. A. M. V. D., Segbers, M., Luiting, H. B., Brabander, T., & Verburg, F. A. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01965-x · Cited by 6
“Previously, dosimetry of Lutetium-177-PSMA ( 177 Lu-PSMA) identified the salivary glands as dose-limiting organs for RNT with 177 Lu-PSMA [10–12].”
BackgroundKao, Y. H., Falzone, N., Pearson, M., Pook, D. W., & Sivaratnam, D. A. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005390 · Cited by 6
Advances in PSMA-Targeted Radionuclide Therapeutics
Ruder, S. F., Ricaurte‐Fajardo, A., Sun, M., Castellanos, S. H., Osborne, J. R., & Tagawa, S. T. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01296-7 · Cited by 6
“Tumor retention of radioactivity can be determined with SPECT/CT after administration of beta emitting TRT. Tumor radiation dose estimated by SPECT/CT, also known as tumor dosimetry, has been associated with beneficial clinical outcomes in trials of 177Lu-PSMA-I&T [58] and 177Lu-PSMA-617 [59].”
Metadata
- Authors
- Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., Scalzo, M., Murphy, D., Williams, S., Hicks, R. J., & Hofman, M. S.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2018-10-05
- Volume
- 60
- Issue
- 4
- Pages
- 517-523
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2895593497
- Cited by
- 504
- References
- 52
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 85 · 2023: 75 · 2022: 61 · 2021: 81 · 2020: 38 · 2019: 22 · 2018: 2
- FWCI
- 24.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Australian Nuclear Science and Technology Organisation
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-PSMA-617, prostate-specific membrane antigen, castration-resistant prostate cancer, metastatic prostate cancer, radiation dosimetry, absorbed dose, PSMA PET/CT, 68Ga-PSMA-11, quantitative SPECT/CT, parotid gland dose, kidney dose, PSA response, treatment outcome prediction, body mass
- MeSH terms
- Single Photon Emission Computed Tomography Computed Tomography, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Neoplasm Metastasis, Radioisotopes, Radiometry, Treatment Outcome, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
